ACCESS LIFE.

ACCESS ANTIBODIES.

WELCOME TO THE WEBSITE OF THE LABORATORY OF JEFF LEYTON PHD FOR THE DEVELOPMENT OF NEXT-GENERATION BIOPHARMACEUTICALS

ABOUT Access antibodies

Access Antibodies focuses on developing innovating technologies that enable the intracellular access of antibody-based pharmaceuticals while maintaining target cell specificity. We leverage our technology platform to develop biopharmaceuticals that deliver cytotoxic payloads more efficiently into target tumor cells or to target 'undruggable' structures. In addition, we develop radiopharmaceuticals to provide improved tumor detection, increased radiation DNA damage, and to aide antibody-drug development.

Access Antibodies is a team effort including local and international students, postdocs, professional researchers, and physicians supervised by Dr. Jeff Leyton.

Current applications are against breast cancer and muscle invasive bladder cancer and always eager to partner with experts in additional diseases.

We engage with the local community to help improve the development of our biopharmaceuticals and, in turn, give back to patients.

Innovative approach to overcome challenges with antibody-based medicines

research topics

PLATFORM FOR ANTIBODY INTRACELLULAR ACCESS

principal investigator

Jeff Victor Leyton Ph.D

2013 - present

Associate Professor 

  • Twitter
  • YouTube
  • Instagram

Dept. of Nuclear Medicine and Radiobiology

Faculty of Medicine and Health Sciences

Université de Sherbrooke

Quebec, Canada

team 

Collaborators

ASSOCIATE PROFESSOR

Jeffrey V. Leyton

Department of Nuclear Medicine and Radiobiology

Université de Sherbrooke

3001 12e Ave Nord

Sherbrooke, Quebec, J1H5N4, Canada

Site by Jeff Leyton